Kythera Labs, a leading data science platform provider for healthcare, announced financing led by Espresso Capital and advised by Brentwood Capital Advisors to support unprecedented growth and enhance its current offerings.

Arkuda Therapeutics secured $64 million in Series B financing. This adds to the $44 million Series A the company achieved in November 2019.

Ventus Therapeutics, which is developing therapies aimed at diseases of the innate immune system, closed a $140 million Series C financing round that will be used to drive three lead programs into the clinic during 2022.

Kyverna Therapeutics secured an additional $85 million following a successful Series B financing round to support various projects in the company’s pipeline of therapies for autoimmune and inflammatory diseases. 

Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.

Amgen sign Thousand Oaks California

Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.

San Francisco-based biotech company Alumis, formerly Esker Therapeutics, closed on a $200 million Series B financing round.

Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.

Investors Hand Disc Medicine $90 Million to Control Hematological Diseases Published: Sept. 2, 2021 By Heather McKenzie BioSpace   A two-year-old biopharma company tackling rare blood diseases has received a $90 million infusion of cash. Disc Medicine, which is progressing a pipeline of clinical-stage therapies for hematologic illnesses including myelofibrosis and porphyrias, announced the Series […]